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Abstract
Drug induced toxic epidermal necrolysis and Stevens Johnson syndrome are more commonly
associated with medications such as sulfonamides, penicillin, anticonvulsants, oxicam non-steroidal
anti-inflammatory drugs, allopurinol and corticosteroids. Isolated instances secondary to drugs
outside of the aforementioned classes have also been reported. We report a case of probable toxic
epidermal necrolysis induced by fluconazole in a 52 year old woman.
Introduction
Adverse cutaneous reactions to drugs are common occur-
rences, affecting 2-3% of hospitalized patients [1]. Drug
induced Toxic Epidermal Necrolysis (TEN) and Stevens
Johnson Syndrome (SJS) are more commonly associated
with medications such as sulphonamides, penicillin and
other antibiotics, anticonvulsants, oxicam NSAIDS, allop-
urinol and corticosteroids. Isolated instances of TEN and
SJS secondary to drugs that do not belong to the afore-
mentioned classes have also been reported. A Medline lit-
erature search revealed only three previously reported
cases of mucocutaneous drug reactions secondary to flu-
conazole therapy. We report a case of fluconazole induced
toxic epidermal necrolysis.
Case presentation
A 52-year-old unemployed Caucasian woman with a 45
pack year smoking history and past medical history signif-
icant for depression, peptic ulcer disease and herpes zoster
presented with painful generalized body rash. The rash
involved greater than 80% of the body surface area and
occurred five days after beginning treatment with 150 mg
daily dose of oral fluconazole for esophageal candidiasis.
Medications prior to admission included sertraline and
esomeprazole, which she had taken for at least one year
without any recent change in dose. There were no prodro-
mal symptoms and the patient was afebrile. Initially
involving the anterior trunk, the rash later spread periph-
erally to involve the rest of the trunk, upper and lower
extremities, face, palms and soles. She also developed
marked lip and oral blisters. Nikolsky's sign was absent.
Over a course of 6 days the rash progressed from ill
defined discrete and confluent macules to blisters. (Fig-
ures 1, 2, 3, 4 and 5)
A diagnosis of fluconazole induced toxic epidermal
necrolysis (Naranjo score 6) was made based on the clin-
ical picture. A skin biopsy later revealed necrolysis of all
epidermal layers with focal epidermal detachment. Labo-
ratory studies revealed a normal WBC count (6.2), mildly
elevated liver enzymes (ALT 45 IU/L, AST 61 IU/L ALK
135 IU/L) and pancreatic amylase (112 IU/L). Blood cul-
tures grew no organisms. She declined HIV testing. In-
hospital management included pain control, skin, mouth
and eye care, intravenous hydration and withdrawal of
fluconazole following which the lesions gradually
resolved.
Published: 20 November 2009
Cases Journal 2009, 2:9071 doi:10.1186/1757-1626-2-9071
Received: 23 May 2009
Accepted: 20 November 2009
This article is available from: http://www.casesjournal.com/content/2/1/9071
© 2009 Ofoma and Chapnick; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cases Journal 2009, 2:9071 http://www.casesjournal.com/content/2/1/9071
Page 2 of 4
(page number not for citation purposes)
Discussion
A response to a drug, which is noxious and unintended
and which occurs at doses normally used for prophylaxis,
diagnosis or therapy of disease, or for the modification of
physiologic function, is classified as an adverse drug reac-
tion [2]. Type A reactions are dose dependent and predict-
able whereas type B reactions (idiosyncratic) are dose
independent. When such a response leads to changes in
the structure and/or function of the skin, its appendages
or mucous membrane, resulting in outcomes such as
death, life-threatening events, hospitalization, disability
or interventions to prevent permanent impairment or
damage, a severe cutaneous adverse drug reaction is said
to have occurred [3]. Classic severe drug reaction patterns
include angioedema/anaphylaxis, exfoliative dermatitis,
Stevens-Johnson syndrome and toxic epidermal necroly-
sis and drug hypersensitivity syndromes [4].
TEN and SJS are acute and life threatening disorders of
unclear pathophysiology. Epidermal necrosis causes ero-
sions of the mucous membranes, extensive detachment of
the epidermis, and severe constitutional symptoms [1,5]
Cases with less than 10% of the epidermis involved are
designated as SJS; those with 30% involvement of the epi-
TEN; Note the widespread dusky rash Figure 1
TEN; Note the widespread dusky rash.
TEN; Widespread rash with skin peeling off in left upper  extremity, anterior trunk and lateral thigh Figure 2
TEN; Widespread rash with skin peeling off in left 
upper extremity, anterior trunk and lateral thigh.
TEN; Rash on anterior chest Figure 3
TEN; Rash on anterior chest. Note involvement of the 
mouth.
TEN; More subtle rashes on plantar aspect of feet Figure 4
TEN; More subtle rashes on plantar aspect of feet. 
Note blistering of the skin overlying the metatarsophalangeal 
joints.Cases Journal 2009, 2:9071 http://www.casesjournal.com/content/2/1/9071
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dermis are labelled as TEN; and cases with between 10
and 30% involvement are defined as overlap SJS-TEN [6].
While SJS can be caused by medications and/or infection,
TEN is almost always drug induced [1,5,7]. More than 100
drugs have been implicated as causes of SJS and TEN in
case reports, but there is a very strong association with
specific medications (Table 1) [4], in nearly 80% of cases
[1,5,8-12] Sulfonamides, anticonvulsants and allopurinol
are the most consistently associated.
The pathophysiologic mechanisms for SJS and TEN are
still obscure but immunologic mechanisms, reactive drug
metabolites and interactions between the two have been
proposed [4]. Studies have suggested that the metabolic
pathway of TEN involves an imbalance in activation and
detoxification mechanisms. This condition may result
from an inherited or acquired deficiency in phase 2
detoxification enzymes and from an increase in the cyto-
chrome P450 (CP450) isoform(s) responsible for process-
ing the culprit drug to reactive metabolites These
metabolic idiosyncrasies can lead to increased levels of
compounds serving as potential immunogens or showing
a direct cytotoxic effect [13].
Underlying diseases, particularly those that compromise
immunity, may also play a role in inducing SJS or TEN
[14,15]. Patients with SLE or HIV have an increased inci-
dence of these syndromes [15-17]. The higher incidence
of TEN found in patients with AIDS may be due to glu-
tathione deficiency, as glutathione conjugation to reactive
metabolites is a major pathway of detoxification [13].
Fluconazole belongs to the azole group of antifungals,
which act by reducing ergosterol synthesis by inhibiting
fungal cytochrome P450 enzymes. It is utilized for most
Candida  infections, coccidioidal meningitis, treatment
and secondary prophylaxis of cryptococcal meningitis and
empiric treatment of critically ill patients. In addition, flu-
conazole is used prophylactically to reduce fungal disease
in bone marrow transplant recipients. Fluconazole is also
a known inhibitor of the human cytochrome P450 system
particularly the isozymes CYP1A2 (weak), 2C9 (strong),
2C19 (strong) and 3A4 (moderate). We can therefore
hypothesize that deficiency of phase 2 substrate (glutath-
ione), as well as immunological response to antigens are
the predominant mechanisms for this adverse drug reac-
tion.
Fluconazole has previously been implicated twice in the
medical literature as a cause of SJS or TEN. Of the two pre-
viously reported cases, one involved a 30-year-old homo-
sexual man who developed SJS following treatment with
fluconazole for oral candidiasis. He was found to be HIV-
positive [18]. The other involved a 33-year-old HIV
infected man who developed TEN following treatment
TEN; Widespread rash involving the lower extremities Figure 5
TEN; Widespread rash involving the lower extremi-
ties.
Table 1: Drugs Associated with Stevens Johnson Syndrome and 
TEN
More Frequently Less Frequently
Sulphadoxine Cephalosporins
Sulphadiazine Fluoroquinolones
Sulphasalazine Vancomycin
Cotrimoxazole Rifampin
Hydantoins Ethambutol
Carbamazepine Fenbufen
Barbiturates Tenoxicam
Phenylbutazone Tiaprofenic acid
Piroxicam Diclofenac
Chlomezone Sulindac
Allopurinol Ibuprofen
Amithiozone Ketoprofen
Aminopenicillins Naproxen
Adapted from Nirken, MH. Stevens-Johnson syndrome and toxic 
epidermal necrolysis in adults. In: UpToDate, Rose, BD (Ed), 
UpToDate, Waltham, MA, 2006 [4]Publish with BioMed Central    and   every 
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with this agent for dysphagia due to recurrent oral thrush
[19]. Lester et al [20], reported diffuse exfoliative drug
reaction in a 30-year-old patient with the acquired
immuno-deficiency syndrome (AIDS) who had been on
fluconazole for oral thrush. This patient demonstrated
mucosal sparing and a clear clinical distinction between
widespread bullous fixed drug eruption and TEN could
not be made. We report a case of severe, latent, type B
TEN. Our patient had history suspicious for immunosup-
pression, probably secondary to HIV infection but
declined testing. To our knowledge, this is the third
reported case of SJS/TEN secondary to fluconazole.
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